Teva Pharmaceutical Industries Ltd. — Report Publication Announcement 2014

Sep 14, 2014

_________ false

C002��� ������ ��������� ��"�2PublicTEVA- PHARMACEUTICAL INDUSTRIES LTD10205Corporation no: 520013954Stock Exchange/Market: NYSE310380P.O.B 3190 , Petach Tikva 49131 , ,Tel: 03-9267267 , 03-9267652 Fax: 03-9267519E.mail address: tomer.amitai@teva.co.ilReported via MAGNA: 14/09/2014              Time of broadcast: 08:57 08:56:48

Reference: 2014-02-156627

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting.
Laquinimod_ECTRIMS_Long-Term_Safety_PR-ENG-HEB_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure: 03/09/2014
- - -
Name of the Signatory: : Bergwerk Dov , Position of Signatory in the reporting corporation: Vice President & General Counsel , Name of Employer Company: .
Basel Telephone: 03-9267513 , Facsimile: 03-9267429 , E-mail: einat.barzilai@teva.co.il 1